Table 1 Therapeutic strategies to overcome heterogeneity of tumor immune microenvironment
From: Heterogeneity of the tumor immune microenvironment and its clinical relevance
Strategies | Regimen | Condition | Trial ID |
|---|---|---|---|
Targeting common antigen | CD19 CAR-T | B-lineage NHL | NCT03029338, NCT02030834 |
EGFR CAR-T | Lung, liver, stomach | NCT03179007, NCT03525782 | |
Mesothelin CAR-T | Ovarian, cervical, pancreatic, lung | NCT01583686 | |
Muc-1 CAR-T | Advanced solid tumors | NCT03179007, NCT03525782 | |
EpCAM CAR-T | Colon, pancreatic, prostate, gastric, liver | NCT03013712 | |
GD2 CAR-T | Glioblastoma | NCT04099797 | |
CEA CAR-T | Multiple tumor types | NCT02349724 | |
Glypican-3 CAR-T | Liver | NCT02932956 | |
DLL-3 CAR-T | Lung | NCT03392064 | |
Gp100 CAR-T | Melanoma | NCT03649529 | |
MAGE-A10 TCR-T | NSCLC | NCT02592577 | |
NY-ESO-1 TCR-T | Ovarian, melanoma, NSCLC | NCT01567891, NCT01350401, NCT02588612 | |
AFP TCR-T | Liver | NCT03132792 | |
MAGE-A3 TCR-T | Advanced solid tumors | NCT02153905 | |
WT1 TCR-T | Mesothelioma, NSCLC | NCT02408016 | |
HPV-16 E7 TCR-T | HPV-associated tumors | NCT02858310 | |
MART-1 TCR-T | Melanoma | NCT00706992 | |
EBV LMP2 TCR-T | NPC | NCT03925896 | |
Prevailing with a multi-targeting strategy | Sequential CD19, CD20 CAR-T | B-lineage NHL | NCT03207178 |
CD19-CD20 dual CAR-T | B-lineage NHL | NCT03398967, NCT03019055 | |
CD19-CD22 dual CAR-T | B-lineage NHL | NCT03593109, NCT-3468153, NCT03233854 | |
Boosting immunogenic cell death and epitope spreading | T-VEC + pembrolizumab | Head and neck squamous cell carcinoma | NCT02626000 |
HF-10 + ipilimumab | Melanoma | NCT02272855 | |
ONCOS-102 + cyclophosphamide | Advanced solid tumors | NCT01598129 | |
ONCOS-102 + pembrolizumab | Melanoma | NCT03003676 | |
OBP-301 + pembrolizumab | Advanced solid tumors | NCT03172819 | |
NeoVax + ipilimumab | Melanoma | NCT03929029 | |
PGV001 + Poly-ICLC | Advanced solid tumors | NCT02721043 | |
AutoSynVax + QS-21 | Advanced solid tumors | NCT02992977 | |
mRNA-4157 | Advanced solid tumors | NCT03313778 | |
Radiotherapy + ipilimumab | Melanoma | NCT01449279 | |
Radiotherapy + immature dendritic cells | Advanced solid tumors | NCT00278018 | |
Microwave ablation | Liver | NCT02851784 |